Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

Masanori Miwa, Masako Ura, M Nishida, +6

European Journal of Cancer

Medicinal ChemistryCancer TissueMedicinePharmacologyHuman Liver +6

Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5?-deoxy-5-fluorouridine

Hiroyuki Eda, Kaori Fujimoto, Shinichi Watanabe, +5

Cancer Chemotherapy and Pharmacology

Cancer ResearchCytokineOncogenic AgentImmunologyCell Death +8

The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, Capecitabine

Nobuo Shimma, Isao UMEDA, M. Arasaki, +10

Bioorganic & Medicinal Chemistry

Medicinal ChemistryPolymer-drug ConjugateMedicineFluorous SynthesisAnti-cancer Agent +4

A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU, in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU

Yuko Tsukamoto, Yukio Kato, Masako Ura, +4

Pharmaceutical Research

Enhanced DNA synthesis of cultured vascular smooth muscle cells from spontaneously hypertensive rats Difference of response to growth factor, intracellular free calcium concentration and DNA synthesizing cell cycle

Masanori Hamada, Ichiro Nishio, Akira Baba, +6

Atherosclerosis

Growth FactorEnhanced Dna SynthesisPhysiologyDna ReplicationCell Culture +6

The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase.

Hiroyuki Eda, Masako Ura, K F-Ouchi, +3

PubMed

Dcyd KinasePharmacotherapyAntimicrobial ChemotherapyPharmaceutical ChemistryTumor Biology +18

High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine.

Masanori Miwa, Hiroyuki Eda, Masako Ura, +4

PubMed

PathologyPharmacotherapyHuman Cancer XenograftsTumor BiologyMedicinal Chemistry +16

Investigation of 5‐FU disposition after oral administration of capecitabine, a triple‐prodrug of 5‐FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5‐FU exposures in the tumour tissue between human and xenograft model

Yuko Tsukamoto, Yukio Kato, Masako Ura, +4

Biopharmaceutics & Drug Disposition

Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine

Kazuo Hattori, Yasunori Kohchi, Nobuhiro Oikawa, +11

Bioorganic & Medicinal Chemistry Letters

Medicinal ChemistryTumor-activated ProdrugMedicineCombination TherapyPharmacotherapy +6

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study

Motoo Nagane, Yasuko Hayashi, Ayaka Shimizu, +2

Japanese Journal of Clinical Oncology